Shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) have been assigned a consensus recommendation of “Buy” from the eight research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $13.42.
Several brokerages recently commented on BLCM. BidaskClub raised Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 14th. Zacks Investment Research raised Bellicum Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a research report on Friday, November 9th. ValuEngine raised Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, October 22nd. Cantor Fitzgerald set a $18.00 price target on Bellicum Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 7th. Finally, Citigroup cut their price objective on Bellicum Pharmaceuticals from $22.00 to $19.00 and set a “buy” rating for the company in a research report on Thursday, August 9th.
Shares of NASDAQ BLCM opened at $4.57 on Monday. Bellicum Pharmaceuticals has a 52 week low of $3.88 and a 52 week high of $10.40. The company has a quick ratio of 8.01, a current ratio of 8.01 and a debt-to-equity ratio of 0.39. The company has a market cap of $198.16 million, a P/E ratio of -1.61 and a beta of 1.09.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.03. The company had revenue of $0.29 million for the quarter, compared to analyst estimates of $0.07 million. As a group, equities research analysts anticipate that Bellicum Pharmaceuticals will post -2.39 EPS for the current year.
In other Bellicum Pharmaceuticals news, Director Jon P. Stonehouse acquired 10,000 shares of the business’s stock in a transaction dated Friday, November 9th. The stock was bought at an average cost of $4.56 per share, with a total value of $45,600.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $45,600. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 9.84% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in BLCM. BNP Paribas Arbitrage SA increased its stake in shares of Bellicum Pharmaceuticals by 161.4% during the second quarter. BNP Paribas Arbitrage SA now owns 16,949 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 10,466 shares during the period. Swiss National Bank increased its stake in shares of Bellicum Pharmaceuticals by 32.3% during the second quarter. Swiss National Bank now owns 58,600 shares of the biopharmaceutical company’s stock worth $432,000 after purchasing an additional 14,300 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in shares of Bellicum Pharmaceuticals during the third quarter worth approximately $110,000. Vanguard Group Inc. increased its stake in shares of Bellicum Pharmaceuticals by 1.2% during the third quarter. Vanguard Group Inc. now owns 1,947,842 shares of the biopharmaceutical company’s stock worth $11,999,000 after purchasing an additional 23,410 shares during the period. Finally, Jefferies Group LLC increased its stake in shares of Bellicum Pharmaceuticals by 117.9% during the third quarter. Jefferies Group LLC now owns 46,799 shares of the biopharmaceutical company’s stock worth $288,000 after purchasing an additional 25,325 shares during the period. 56.13% of the stock is owned by institutional investors.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.
Featured Story: Understanding Average Daily Trade Volume
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.